Evidence map›Paper›PMID 39800048›Full record

ArticleNeuroscience2025

Assessment of complementary white matter microstructural changes and grey matter atrophy in the 6-OHDA-induced model of Parkinson's disease.

Maurizio Bergamino, Alberto Fuentes, Ivette M Sandoval, David J Marmion, Christopher Bishop, Fredric P Manfredsson, Ashley M Stokes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maurizio BergaminoBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
Alberto FuentesBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
Ivette M SandovalBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
David J MarmionBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
Christopher BishopDepartment of Psychology, Binghamton University, Binghamton, NY, 13902, USA.
Fredric P ManfredssonBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
Ashley M StokesBarrow Neuroimaging Innovation Center, Barrow Neurological Institute, Phoenix, AZ, 85013, USA. Electronic address: ashley.stokes@barrowneuro.org.

Funding

Interrogating Maladaptive Serotonin Raphe-Striatal Plasticity in L-DOPA-Induced DyskinesiaR01NS122226 · NINDS · STATE UNIVERSITY OF NY,BINGHAMTON · PI CHRISTOPHER R BISHOP, Fredric Manfredsson · 2022 to 2026
$3.1M
Multi-scale functional connectivity in preclinical models of Parkinson's diseaseR01NS124575 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI Ashley M Stokes · 2022 to 2026
$2.0M
NINDS NIH HHS R01 NS122226NINDS NIH HHS R01 NS124575
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder that is characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Magnetic resonance imaging (MRI) offers a non-invasive means to study PD and its progression. This study utilized the unilateral 6-hydroxydopamine (6-OHDA) rat model of parkinsonism to assess whether white matter microstructural integrity measured using advanced free-water diffusion tensor imaging metrics (fw-DTI) and gray matter density using voxel-based morphometry (VBM) can serve as imaging biomarkers of pathological changes following nigrostriatal denervation. By comparing the 6-OHDA-lesioned vs. sham-lesioned rats, we aimed to identify complementary gray matter and white matter changes indicative of disease pathophysiology. Results showed widespread gray matter atrophy and subtle changes in white matter integrity in the 6-OHDA lesioned rats. Gray matter atrophy predominantly affected ipsilateral cortical regions, with some bilateral regions also showing atrophy. Conversely, higher volumes were observed in some regions of the contralateral gray matter in the 6-OHDA model. Furthermore, increased fw-FA and fw-AX were observed in regions including the brainstem, thalamus, superior and inferior colliculus, and fornix. Smaller clusters of decreased fw-FA and fw-AX were found in the corpus callosum. Regions of both increased and decreased diffusivity were noted in fw-RD, primarily in the brainstem, while the f index was elevated in several regions in the 6-OHDA lesioned group, except for a cluster in the contralateral thalamus. In conclusion, this study underscores the significant potential role for gray and white matter imaging biomarkers in delineating disease pathology in parkinsonism.

Indexed as

BrainGray MatterParkinson DiseaseParkinsonian DisordersWhite MatterAnimalsAtrophyDiffusion Tensor ImagingDisease Models, AnimalMaleOxidopamineRatsRats, Sprague-DawleyOxidopamine6-hydroxydopamineDiffusion magnetic resonance imagingFree water diffusion tensor imagingParkinson’s diseaseVoxel-based morphometry

Identifiers

PMID39800048
PMCPMC11871993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.